Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Medizin & Biologie

• Endometrial Neoplasms 100%
• Placebos 59%
• Confidence Intervals 58%
• Microsatellite Instability 39%
• Progression-Free Survival 39%
• Carboplatin 24%
• Paclitaxel 21%
• Programmed Cell Death 1 Receptor 15%
• Response Evaluation Criteria in Solid Tumors 13%
• DNA Mismatch Repair 12%
• Population 12%
• Body Surface Area 12%
• Survival 11%
• Alopecia 11%
• Combination Drug Therapy 10%
• Random Allocation 10%
• Nausea 9%
• Immunotherapy 9%
• Fatigue 9%
• Research Personnel 7%
• Randomized Controlled Trials 7%
• Safety 6%
• Therapeutics 3%
• Neoplasms 3%